116 related articles for article (PubMed ID: 8382471)
1. Parathyroid hormone and T-cellular immunity in uremic patients in replacement dialytic therapy.
Angelini D; Carlini A; Giusti R; Grassi R; Mei E; Fiorini I; Mazzotta L; Antonelli A
Artif Organs; 1993 Feb; 17(2):73-5. PubMed ID: 8382471
[TBL] [Abstract][Full Text] [Related]
2. Immunologic disturbances and levels of parathyroid hormone in uremic patients in replacement dialysis therapy.
Angelini D; Carlini A; Mazzotta L; Mei E; Grassi R; Giusti R; Neri M; Fiorini I; Antonelli A
Clin Nephrol; 1994 Oct; 42(4):246-50. PubMed ID: 7834917
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunity and levels of parathyroid hormone in uremic patients receiving hemodialysis.
Griveas I; Visvardis G; Papadopoulou D; Mitsopoulos E; Kyriklidou P; Manou E; Meimaridou D; Ginikopoulou E; Sakellariou G; Fleva A; Zilidou R; Paulitou A
Ren Fail; 2005; 27(3):275-8. PubMed ID: 15957542
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of secondary hyperparathyroidism on circulating CD4+ and CD8+ T-lymphocytes in chronic renal failure patients.
El Kelany MA; Maklad SS; El Fouhil DF; El Etreby EA; Saleh LH; El Sheikh NA
Egypt J Immunol; 2009; 16(2):71-82. PubMed ID: 22059355
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia.
Avram MM; Sreedhara R; Avram DK; Muchnick RA; Fein P
Am J Kidney Dis; 1996 Dec; 28(6):924-30. PubMed ID: 8957048
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
Bellazzi R; Romanini D; Bacchella L; Nai M; Aprile C; Santagostino M; De Vincenzi A
Nephron; 1991; 57(3):273-82. PubMed ID: 2017266
[TBL] [Abstract][Full Text] [Related]
8. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
9. Hyperparathyroidism: is it really the major factor affecting glucose tolerance in uremia?
Bergesio F; Bandini S; Cresci B; Monzani G; Rotella C; Conti A; Rosati A; Piperno R; Messeri G; Frizzi V; Salvadori M
Miner Electrolyte Metab; 1996; 22(1-3):187-91. PubMed ID: 8676816
[TBL] [Abstract][Full Text] [Related]
10. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
11. T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease.
Kaneko T; Osono E; Hayama N; Lino Y; Terashi A
Clin Nephrol; 1997 Dec; 48(6):353-8. PubMed ID: 9438093
[TBL] [Abstract][Full Text] [Related]
12. Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. A pilot study.
Lind L; Wengle B; Wide L; Wrege U; Ljunghall S
Nephron; 1988; 48(4):296-9. PubMed ID: 3362275
[TBL] [Abstract][Full Text] [Related]
13. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
Avram MM; Feinfeld DA; Huatuco AH
N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients.
Coppolino G; Bolignano D; De Paola L; Giulino C; Mannella A; Riccio M; Mascaro MA; Lombardi G; Fuiano G; Lombardi L; Buemi M
J Investig Med; 2011 Jun; 59(5):823-8. PubMed ID: 21383630
[TBL] [Abstract][Full Text] [Related]
15. Sexual influence on bone metabolism in uremic patients on regular dialytic treatment.
Luisetto G; Bertoli M
Nephron; 1994; 67(2):150-7. PubMed ID: 8072603
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related peptide plasma concentrations in patients on hemodialysis.
Nordholm A; Rix M; Olgaard K; Lewin E
Scand J Clin Lab Invest; 2014 Apr; 74(3):206-12. PubMed ID: 24456420
[TBL] [Abstract][Full Text] [Related]
17. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
Quarles LD; Lobaugh B; Murphy G
J Clin Endocrinol Metab; 1992 Jul; 75(1):145-50. PubMed ID: 1619003
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function.
Gao P; Scheibel S; D'Amour P; John MR; Rao SD; Schmidt-Gayk H; Cantor TL
J Bone Miner Res; 2001 Apr; 16(4):605-14. PubMed ID: 11315988
[TBL] [Abstract][Full Text] [Related]
19. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
[TBL] [Abstract][Full Text] [Related]
20. Role of parathormone levels on T-cell response in hemodialysis patients.
Ozdemir FN; Yakupoglu U; Turan M; Arat Z; Karakayali H; Erdal R; Turan M
Transplant Proc; 2002 Sep; 34(6):2044-5. PubMed ID: 12270308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
